Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
ATG (Horse), Cyclosporine, Eltrombopag Variant #01 | — | R 999 867 | 180d | — | — | ~1 | ~R 999 867 indirect | — |
ATG (Rabbit) and Cyclosporine Variant #01 | — | R 318 554 | — | — | — | ~1 | ~R 318 554 indirect | — |
ATG (Horse), Cyclosporine, Sirolimus Variant #01 | — | R 279 897 | 180d | — | — | ~1 | ~R 279 897 indirect | — |
ATG (Horse), Cyclosporine, G-CSF Variant #01 Partial | — | R 177 615 | — | — | — | ~1 | ~R 177 615 indirect | — |
ATG (Horse) and Cyclosporine Variant #02 | — | R 114 536 | — | — | — | ~1 | ~R 114 536 indirect | — |
ATG (Horse), Cyclosporine, Methylprednisolone Variant #01 Partial | — | R 51 346 | — | — | — | ~1 | ~R 51 346 indirect | — |
Cyclosporine monotherapy Variant #03 | — | R 29 855 | — | — | — | ~1 | ~R 29 855 indirect | — |
7 of 7 regimens shown